Autolus Therapeutics
AUTL1.9002.56% ( -0.050 )
Autolus Therapeutics (AUTL)
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the Unite...
- Open
- 1.950
- High
- 1.980
- Low
- 1.840
- Prev. Close
- 1.950
- Volume
- 1.58M
- Turnover
- 2.99M
- Avg Price
- 1.899
- Bid/Ask Ratio
- --
- Amplitude
- 7.18%
- 52wk High
- 2.520
- Volume Ratio
- 2.00
- Turnover Ratio
- 1.34%
Autolus Therapeutics Analyst Rating
View MoreForecast & Rating
Aug 5, 2026Price forecast
$8.68356.58%
Forecast & RatingStrong buy
9analysts
- Strong buy88.89%
- Buy11.11%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- rttnews · 1 day ago, 09:33 PM
Top Biotech Gainers: UPC Cuts Loss, CPIX Gains Ahead Of Q2 Results, AUTL Builds Commercial Momentum
- PUBT · 2 days ago, 03:09 PM
Autolus Therapeutics schedules second-quarter financial results release and conference call
- Market Beat · 2 days ago, 12:40 PM
Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up - Still a Buy?
- benzinga_article · 2 days ago, 12:05 PM
12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga_article · 2 days ago, 09:00 AM
CNH Industrial Posts Upbeat Q2 Earnings, Joins Autolus Therapeutics, Bowhead Specialty Holdings And Other Big Stocks Moving Higher On Monday
- PUBT · 2 days ago, 06:13 AM
Autolus raises FY 2026 sales forecast to $140 million-$150 million
